Los Angeles, CA, United States
Los Angeles, CA, United States

Time filter

Source Type

The present invention relates to methods of predicting the risk for colectomy in a subject with mrUC, by determining the presence or absence of one or more mrUC risk variants. Other embodiment, relate to methods of treating mrUC in a subject and a kit for prognostic use.


Patent
Cedars Sinai Medical Center | Date: 2016-05-24

An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.


In various embodiments, the present application discloses systems and methods for magnetic resonance imaging (MRI) of coronary arteries. In various embodiments, the invention allows for motion corrected, simultaneously acquired multiple contrast weighted images with whole-heart coverage and isotropic high resolution. In some embodiments, the invention teaches using interleaved preparatory pulses, a 3D radial golden angle trajectory and 100% respiratory gating efficiency.


Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohns disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.


Patent
Cedars Sinai Medical Center | Date: 2015-06-04

Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH+MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.


Patent
Cedars Sinai Medical Center | Date: 2017-04-19

The invention describes compounds that inhibit both HDAC and GSK3 (i.e., HDAC/GSK3 dual inhibitors). The invention further describes compositions containing these HDAC/GSK3 dual inhibitors, as well as methods and kits using these HDAC/GSK3 dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3 to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3. Medical conditions treatable with various embodiments of the invention include but are not limited to caners and tumors.


Patent
Cedars Sinai Medical Center and City University of New York | Date: 2016-10-24

The invention provides methods for treating brain insulin resistance and/or diseases associated therewith in a subject in need thereof. The methods include providing a composition comprising a dual GLP-1 receptor/GIP receptor (GLP-1R/GIPR) agonist and administering an effective amount of the composition to the subject to treat brain insulin resistance and diseases associated therewith.


Patent
Cedars Sinai Medical Center and Board Of Regents Of The University Of Texas System | Date: 2016-09-28

The present invention describes a method of using an ultrasonic bath to enhance tissue perfusion, enhance the development of collateral blood vessels and/or enhance collateral circulation in an extremity in need thereof. Also described is an ultrasonic bath for the inventive method.


Patent
Cedars Sinai Medical Center | Date: 2017-04-12

Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH + MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.


Patent
Cedars Sinai Medical Center and University of Michigan | Date: 2015-07-09

Described herein are kits and methods for identifying the likelihood of having a food sensitivity or intolerance, and determining dietary modifications accordingly. For example, the likelihood of having sensitivities, intolerances or allergies to gluten, lactose, FODMAPs and others tested and calculated. Additionally, diet modifications can be determined according to the likelihood of particular sensitivities, and the effectiveness of diet modifications can be evaluated by monitoring of meals and subsequent symptoms, and evaluating the monitoring information. Through application of the methods herein, dietary intake and symptom data may be collected and aggregated to evaluate the effect or desirability of particular foods on a population of interest.

Loading Cedars Sinai Medical Center collaborators
Loading Cedars Sinai Medical Center collaborators